BioLineRx (NASDAQ:BLRX) Upgraded at StockNews.com

StockNews.com upgraded shares of BioLineRx (NASDAQ:BLRX) to a sell rating in a research report sent to investors on Tuesday.

Separately, HC Wainwright reaffirmed a buy rating and issued a $21.00 price objective on shares of BioLineRx in a report on Wednesday, April 17th.

BioLineRx Stock Performance

Shares of NASDAQ BLRX opened at $0.61 on Tuesday. The company has a current ratio of 1.53, a quick ratio of 1.47 and a debt-to-equity ratio of 0.50. BioLineRx has a 12 month low of $0.55 and a 12 month high of $2.53. The stock has a 50 day moving average of $1.01 and a 200-day moving average of $1.30. The company has a market capitalization of $48.89 million, a P/E ratio of -0.68 and a beta of 1.38.

BioLineRx (NASDAQ:BLRX) last released its quarterly earnings results on Thursday, March 28th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.07. The firm had revenue of $4.80 million during the quarter, compared to the consensus estimate of $0.17 million. During the same quarter last year, the firm earned ($0.09) earnings per share. As a group, equities research analysts predict that BioLineRx will post -1.03 EPS for the current year.

Hedge Funds Weigh In On BioLineRx

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BLRX. NorthRock Partners LLC acquired a new position in shares of BioLineRx during the 4th quarter worth $27,000. B. Riley Wealth Advisors Inc. increased its holdings in BioLineRx by 88.5% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 21,300 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 10,000 shares in the last quarter. Allen Mooney & Barnes Investment Advisors LLC acquired a new position in BioLineRx in the 3rd quarter worth about $46,000. Rathbones Group PLC bought a new stake in shares of BioLineRx in the 3rd quarter valued at about $72,000. Finally, Values First Advisors Inc. bought a new stake in shares of BioLineRx in the 3rd quarter valued at about $88,000. 1.56% of the stock is owned by institutional investors and hedge funds.

BioLineRx Company Profile

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.